摘要:
A novel series of N,N'-bis-methylenedioxybenzyl-alkylenediamines 5a-5g have been designed, synthesized and evaluated as bivalent anti-Alzheimer's disease ligands. The enzyme inhibition assay results indicated that compounds 5e-5g inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the micromolar range (IC50, 2.76-4.24 mu M for AChE and 3.02-5.14 mu M for BuChE), which was in the same potential as the reference compound rivastigmine (IC50, 5.50 mu M for AChE and 1.60 mu M for BuChE). It was found that compounds could bind simultaneously to the peripheral and catalytic sites of AChE. beta-Amyloid (A beta) aggregation inhibition assay results showed that compound 5e exhibited highest self-mediated A beta fibril aggregation inhibition activity (40.3%) with a similar potential as curcumin (41.6%). It was also found that 5e-5g did not affect neuroblastoma cell viability at the concentration of 50 mu M.